A NOVEL TARGETED ONCOLOGY PLATFORM BASED ON VIRUS-LIKE PARTICLES

Virus-like capsid particleOur technology platform represents a novel approach to target a broad range of solid tumors using virus-like particles, or VLPs, derived from the human papillomavirus (HPV) that are designed to enable their use as oncology therapeutics. Our VLPs can be loaded or conjugated with drugs creating a new class of targeted therapies.

TARGETING HSPG EXPRESSING TUMORS

Heparan sulfate proteoglycans or HSPGs are a large family of molecules found in the extracellular matrix (ECM) and on the membranes of cells. Tumors specifically modify HSPGs with key sulfation modifications that provide high binding specificity to a number of ligands. Tumor modified HSPGs regulate many aspects of tumor progression, including proliferation, invasion, angiogenesis and metastases. Our VLPs selectively bind to tumor modified HSPGs and not to normal cells.

DUAL MECHANISM OF ACTION

VDCs are a novel class of drugs with a dual mechanism of action that promotes cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and by activating a secondary immune mediated response. We believe that our VDC platform has the potential to serve as a backbone for a broad portfolio of targeted oncology therapeutics.

Key advantages of VDCs
 

VLP_delivery

DELIVERY
A single VDC can deliver hundreds of cytotoxic molecules conjugated to its capsid proteins.

Tumor cells

HSPG DRIVEN TUMOR TARGETING
Based on the ability of VLPs to selectively recognize specifically modified and overexpressed HSPGs present on many tumor types, VDCs have the potential to be used broadly across a wide range of cancers without binding to normal cells, limiting off-target toxicity.

VLP Binding

BINDING
The VDCs have a high number of HSPG binding sites, and this multi-valency permits the strong and selective binding to tumor cells.

VLP Dual MOA

DUAL MOA
VDCs have a dual mechanism of action, first by acute necrosis of the tumor cells, and subsequently by creating a highly immunogenic milieu that induces an antitumor specific immune response leading to a more robust and durable therapy.

Meet the Team
Meet the Team
Aura has assembled a world-class leadership team.
View Our Pipeline
View Our Pipeline
We are advancing multiple therapeutic candidates based on our VDC technology platform.
AU-011 for Choroidal Melanoma
AU-011 for Choroidal Melanoma
Our lead VDC AU-011 is about to enter late-stage clinical trials.